Skip to content

Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage

Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage: Evidence of Kinematic Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01076257
Enrollment
48
Registered
2010-02-26
Start date
2009-06-30
Completion date
2010-07-31
Last updated
2012-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Damage, Cerebral Palsy, Traumatic Brain Damage

Keywords

brain damage, constraint induced movement therapy, kinematic, function, outcome, Quality of life

Brief summary

This research centers on the comparison of the immediate efficacy (right after therapy) and the maintained efficacy (3 months and 6 months) between Modified Constraint-Induced Movement Therapy (mCIMT) group and control group at different age.

Detailed description

Modified Constraint-Induced Movement Therapy is one of the most recent treatments for children with Brain damage. This well-designed and follow-up RCT study compared home-based CIT with a control intervention (traditional rehabilitation, TR) by combining kinematic analysis and clinical evaluation, which is possible to examine whether functional improvement is accompanied by a change in motor control. We hypothesized that home-based CIT would induce better motor control strategies (shorter RT, MT, lesser MUs, MGA, and PMGA, and larger peak velocity (PV)) for greater functional gains than TR. Furthermore, the beneficial effects would be maintained at 3 and 6 months of follow-up. Findings of this study allow clinicians to understand the underlying motor control changes for functional improvement after home-based CIT.

Interventions

Home based CIT 1. Restriction of the less affected limb 2. Intensive practice using affected limb 3. Positive experience 4. Functional task (task)

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
4 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

1. Development learned-nonuse 2. Age range 4y/o-15y/o 3. Wrist ext 10˚, MP j't ext 10˚ in affected U/E 4. Can fallow up the simple instruction 5. Modified Ashworth Scale ≦2 6. Pediatric Motor Activity Log ≦2.5 (average)

Exclusion criteria

1. Related muscle skeleton surgery 2. Selective dorsal rhizotomy 3. Botulinum toxin in 6 months 4. Visual perception impaired 5. Hearing perception impaired 6. Balance ability impaired (in constrained)

Design outcomes

Primary

MeasureTime frameDescription
Bruininks-Oseretsky Test of Motor Proficiency (BOTMP)4 weeks (post-treatment), 12 week, 24 weekAll children underwent a series of upper limb assessments, including kinematic analysis and functional measures (primary and secondary outcomes), before the start of the intervention (pretreatment). An occupational therapist blinded to group assignment was trained to administer these measures. All participants underwent these assessments at 4 weeks immediately after intervention (post-treatment), and at 12-week follow-up and 24-week follow-up.
Peabody Development Motor Scales, subtest fine motor (PDMS-Ⅱ)4 weeks (post-treatment), 12 week, 24 week
Kinematic analysis4 weeks (post-treatment), 12 week, 24 week

Secondary

MeasureTime frameDescription
Pediatric Motor Activity Log ( PMAL )4 weeks (post-treatment), 12 week, 24 weekAll children underwent a series of upper limb assessments, including kinematic analysis and functional measures (primary and secondary outcomes), before the start of the intervention (pretreatment). An occupational therapist blinded to group assignment was trained to administer these measures. All participants underwent these assessments at 4 weeks immediately after intervention (post-treatment), and at 12-week follow-up and 24-week follow-up.
Pediatric Functional Independence Measure ( WeeFIM )4 weeks (post-treatment), 12 week, 24 week
Cerebral palsy quality of life (CPQoL)4 weeks (post-treatment), 12 week, 24 week

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026